Eli Lilly's Cancer Drug Olomoborib Receives FDA Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Eli Lilly's (LLY) experimental pancreatic cancer treatment, Olomoborib, marking a significant milestone in the company's expansion beyond weight-loss drugs.